Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Rituximab
United Therapeutics Europe Ltd
Kidney Transplant Rejection
1 trial -
Rituximab
The First People's Hospital of Lianyungang
Refractory Myasthenia Gravis
1 trial -
Rivaroxaban 2.5 Mg Oral Tablet
The George Institute
Chronic Kidney Diseases
1 trial -
Rivastigmine Transdermal System
United Therapeutics Europe Ltd
Parkinson Disease
1 trial -
RoActemra 20 mg/mL concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, Vincristine Sulfate 1 mg/ml solution for injection, Neulasta 6 mg solution for injection, AZD0486, RoActemra 20 mg/mL concentrate for solution for infusion, Truxima 500 mg concentrate for solution for infusion, Ribodoxo® 2 mg/ml Injektionslösung, Prednison 20 mg GALEN®, AZD0486, Endoxan 500 mg, poeder voor oplossing voor injectie, Ruxience 500 mg concentrate for solution for infusion
AstraZeneca AB
Large B-cell Lymphoma
1 trial -
Robotic Gastrectomy
The First People's Hospital of Lianyungang
Gastric Cancer (GC)
1 trial -
Roflumilast 0.3% cream
Arcutis Biotherapeutics
Chronic Plaque Psoriasis
1 trial -
Roflumilast Cream
Arcutis Biotherapeutics
Atopic Dermatitis Eczema
1 trial -
Roflumilast Cream 0.05%
Arcutis Biotherapeutics
Atopic Dermatitis Eczema
1 trial -
Roflumilast Cream 0.15%
Arcutis Biotherapeutics
Atopic Dermatitis Eczema
1 trial -
Roflumilast Foam
Arcutis Biotherapeutics
Seborrheic Dermatitis
1 trial -
Roflumilast Foam 0.3%
Arcutis Biotherapeutics
Scalp Psoriasis
1 trial -
Ropivacaine HCL
Atrium Therapeutics
Renal Carcinoma
1 trial -
Ropivacaína Altan 2 mg/ml solución inyectable EFG, Adrenalina B. Braun 1 mg/ml Solución Inyectable
The George Institute
lumbar arthrodesis
1 trial -
Rozlytrek, Rozlytrek, RO 743-5846/F06, Ipatasertib, Rozlytrek, INAVOLISIB, Ipatasertib, INAVOLISIB, RO7538483, Rozlytrek 200 mg hard capsules, Rozlytrek 100 mg hard capsules, Avastin 25 mg/ml concentrate for solution for infusion., Tiragolumab, RO 743-5846/F04, Tecentriq 1 200 mg concentrate for solution for infusion, ABIRATERONE
Hoffmann-La Roche
This is an extension study designed to provide continued treatment for eligible patients with cancer who were previously enrolled and treated in a Genentech/Roche study (the parent study), and do not have access to the treatment locally
1 trial -
Rusfertide 45mg, Rusfertide 60mg, Rusfertide 30mg, Rusfertide 10mg, Rusfertide 20mg, Placebo to Match PTG-300 for Injection. Formulation (lyophilized powder) is based upon that of PTG-300 for Injection, with the drug substance omitted.
Protagonist Therapeutics, Inc
Polycythemia Vera
1 trial -
Ruxolitinib
Novartis Pharmaceuticals
Polycythemia Vera
1 trial -
Ruxolitinib (INCB018424) cream, Vehicle cream (same formulation of cream as the test product but without active substance and the phosphoric acid)
Incyte
Hidradenitis Suppurativa
1 trial -
Rybelsus 3 mg tablets, Rybelsus 14 mg tablets, Placebo (semaglutide) tablets, Rybelsus 7 mg tablets
NovoThirteen
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type
1 trial -
Rybelsus 7 mg tablets, Placebo (semaglutide) tablets, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets
NovoThirteen
Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type
1 trial -
S-1 therapy
The First People's Hospital of Lianyungang
Carcinoma, Non-Small-Cell Lung
1 trial -
SANDOSTATIN LAR 10 mg powder and solvent for suspension for injection, LysaKare 25 g/25 g solution for infusion, SANDOSTATIN LAR 20 mg powder and solvent for suspension for injection, SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Lutathera 370 MBq/mL solution for infusion
Advanced Accelerator Applications
Patients with somatostatin receptor positive, well-differentiated G2 and G3, advanced GEP NETs
1 trial -
SBRT
United Therapeutics Europe Ltd
Prostate Cancer
3 trials -
SDF solution
The University of Hong Kong
Dental Caries
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources